Regulatory Oversight and Scientific Independence in Pediatric Gender Dysphoria Research: Implications from the UK Pathways Clinical Trial Suspension

Recent regulatory actions surrounding the UK's Pathways clinical trial examining puberty suppression therapy highlight critical tensions between scientific objectivity and institutional oversight in pediatric gender dysphoria research. The excusal of a key regulatory official raises important questions about research governance and evidence generation in this contested clinical domain.